Facebook
X
LinkedIn
ForwardDate & Time of Session - 11/21/25 - from 12:00 - 1:00PM
Overview
Tranexamic acid (TXA) as an antifibrinolytic agent has well-established benefits in trauma-related hemorrhage, yet its utility in non-trauma indications continues to evolve and expand with varying levels of supporting evidence. Emerging studies generate both promising and conflicting data, and pharmacists along with other clinicians, must be able to discern between evidence-based indications and those with limited literature and critically assess the quality of studies to guide decision-making. This presentation will provide a practical, evidence-informed framework to help guide when TXA should, or should not, be incorporated into a treatment plan.
Objectives
Upon completion of this activity, participants will be able to:
1. Define the mechanism of action of tranexamic acid (TXA) as an antifibrinolytic and its role in coagulopathy.
2. Review evidence-based indications for TXA.
3. Evaluate available literature exploring the utility of TXA for indications with limited evidence.
Target Audience
Pharmacists, residents, and students
Special Services
If you require special assistance to attend this event, please call Megan Russell at (304) 550-0896.
Speaker:
Maddie Lee, PharmD, MPA
PGY2 Emergency Medicine Resident
UK College of Pharmacy - Lexington, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.